Related Experiment Videos
Bioactive materials in orthopaedic surgery: overview and regulatory considerations
Thomas W Bauer1, Susanne T Smith
1Department of Pathology, The Cleveland Clinic Foundation Cleveland, OH 44195, USA. osteoclast@aol.com
Clinical Orthopaedics and Related Research
|April 9, 2002
Summary
Orthopaedic surgeons will soon have diverse skeletal substitutes beyond bone grafts, blurring lines between material types. Regulatory pathways for these innovative materials are complex, involving biologic, drug, or medical device classifications.
Area of Science:
- Orthopaedic surgery
- Biomaterials science
- Regulatory science
Background:
- Bone graft remains the gold standard for skeletal reconstruction.
- Emerging skeletal substitutes include inert materials, resorbables, bioactive materials, tissues, engineered tissues, drugs, and composites.
- These materials exhibit osteogenic, osteoconductive, or osteoinductive properties.
Purpose of the Study:
- To review the evolving landscape of skeletal substitutes for orthopaedic reconstruction.
- To discuss the classification and regulatory pathways for novel biomaterials in the United States.
- To highlight the complexities in regulating materials as biologics, drugs, or medical devices.
Main Methods:
- Literature review of current and emerging skeletal substitute materials.
- Analysis of regulatory frameworks governing biomaterials by the Food and Drug Administration (FDA).
- Examination of approval processes, including Premarket Notification (510(K)) and Premarket Approval Application (PMA).
Main Results:
- The distinction between different types of skeletal substitutes is becoming less clear.
- Regulatory control in the U.S. is complex, depending on the material's classification.
- Different FDA agencies oversee various product types, with distinct approval requirements.
Conclusions:
- Orthopaedic surgeons face an expanding array of skeletal reconstruction tools.
- Navigating the regulatory landscape is crucial for the clinical translation of new biomaterials.
- Evolving regulations impact the oversight of even minimally manipulated tissues for transplantation.